Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials

Journal of Infectious Diseases

Volumn 200, Issue 2, 2009, Pages 166-171

  Schiller, John T ^a   Lowy, Douglas R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM SALT; CERAVARIX; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

CLINICAL TRIAL; COMPETITIVE LUMINEX IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENITAL TRACT INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; UTERINE CERVIX CANCER; VIRUS IMMUNITY; VIRUS LIKE AGENT;

ANTIBODIES, VIRAL; HUMANS; IMMUNOASSAY; NEUTRALIZATION TESTS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 67650663521     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/599988     Document Type: Review

References (29)

1. Inglis S, Shaw A, Koenig S. Chapter 11: HPV vaccines: commercial research and development. Vaccine 2006; 24(Suppl 3):S3/99-105.
2. Schiller JT, Castellsague X, Villa L, Hildesheim A. An update of prophylactic human papillomavirus Ll virus-like particle vaccine clinical trial results. Vaccine 2008; 26 (Suppl 10): K53-61.
3. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) Ll viruslike particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118:2135-45.
4. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 Ll virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007;40:564-71.
5. Martino M. Press release: GlaxoSmithKline initiates head-to-head study of cervical cancer vaccines. FierceBiotech, 18 January 2007. Available at: http://www.fiercebiotech.com/ node/5273. Accessed 20 May 2009.
6. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008; 109:S15-21.
7. Zinkemagel RM. On natural and artificial vaccinations. Annu Rev Immunol 2003; 21: 515-46.
8. Nardelli-Haefliger D, Wirthner D, Schiller JT, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003;95:1128- 37.
9. Roberts JN, Buck CB, Thompson CD, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 2007; 13: 857-61.
10. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005;32(Suppl 1):S7-15.
11. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 Ll viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:743-53.
12. Yang R, Murillo FM, Delannoy MJ, et al. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol 2005; 174:7912-9.
13. Harper DM, Franco EL, Wheeler Q et al. Efficacy of a bivalent Ll virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
14. Ferguson M, Heath A, Johnes S, Pagliusi S, Dillner J. Results of the first WHO interna tional collaborative study on the standardization of the detection of antibodies to human papillomaviruses. Int J Cancer 2006; 118: 1508-14.
15. Pastrana DV, Buck CB, Pang YY, et al. Reactivity of human sera in a sensitive, highthroughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004;321:205-16.
16. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10:108-15.
17. Kemp TJ, Hildesheim A, Falk RT, et al. Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies. Clin Vaccine Immunol 2008; 15:60-4.
18. Dessy FJ, Giannini SL, Bougelet CA, et al. Correlation between direct ELISA, single epitopebased inhibition ELISA and pseudovirionbased neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with an AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008;4:425-34.
19. Smith JF, Brownlow M, Brown M, et al. Antibodies from women immunized with Gardasil®cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007;3:109-16.
20. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent Ll virus-like particle vaccine against human papillomavirus types 16 and 18: followup from a randomised control trial. Lancet 2006;367:1247-55.
21. World Health Organization. WHO meeting on the standardization of HPV assays and the role of WHO HPV LabNet in supporting vaccine introduction. Geneva: World Health Organization, 2008. Available at: http://www .who.int/biologicals/areas/vaccines/hpv-labnet/FINAL%20repor-%20HPV-%2023+24 %20+25%20Jan%202008%20-CLEAN-.pdf. Accessed 20 May 2009.
22. Kemp TJ, Garcia-Pineres A, Falk RT, et al. Evaluation of systemic and mucosal antiHPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 2008; 26: 3608-16.
23. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 Ll virus-like particle (VLP) vaccine. Vaccine 2007; 25: 4931-9.
24. Mach H, Volkin DB, Troutman RD, et al. Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). J Pharm Sci 2006;95: 2195-206.
25. Barr E, Tamms G. Quadrivalent human papillomavirus vaccine. Clin Infect Dis 2007; 45: 609-17.
26. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 Ll VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24:5937-49.
27. PharmaTimes.com. Gardasil and Cervarix go head-to-head. 18 January 2007. Available at: http://www.natap.org/2007/newsUpdates/ 012207-04.htm. Accessed 20 May 2009.
28. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 Ll virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459- 66.
29. Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008;26:6844-51.